Introduction {#sec1-1}
============

End-Stage Renal Disease is the final stage of Chronic Kidney Disease (CKD) and its incidence has increased considerably in the last 30 years.^[@ref1]^ The pruritus is defined as an unpleasant and subjective sensation that forces the individual to scratch, it may be localized or generalized, and is a frequent symptom in patients with terminal chronic kidney disease on hemodialysis;^[@ref4]^ it is the most reported dermatological symptom, with a prevalence ranging between 20 and 90%, and, also, it significantly affects the quality of life, the adherence the treatment and the management of associated comorbidities.^[@ref8],[@ref9]^

The pathophysiology of pruritus in patients with terminal chronic kidney disease is not well understood, however, a series of studies have described several factors that could influence the pathogenesis of the problem, including, BUN, serum calcium and phosphorus levels, high Parathyroid Hormone (PTH) levels, a compromised skin barrier, the dose of dialysis (kt/ V), the type of membrane used by the dialysis equipment, among others.^[@ref6],[@ref9]^ Perhaps the most relevant study, which managed to establish the factors associated with pruritus in patients with chronic kidney disease on hemodialysis was the Daily Outcomes and Practice Patterns Study (DOPPS); it was a cohort of 18 801 patients on hemodialysis from 12 different countries and it was determined that male patients, lung disease, congestive heart failure, high phosphorus and calcium levels, and low albumin levels, experienced pruritus more severe than the controls. They also established that there was a slight increase in the severity of pruritus in the first 10 years of illness.^[@ref8]^ In Peru, according to the Reporte del Registro Nacional de Diálisis (RENDES) for 2015, an average of 27 391 patients with terminal chronic kidney disease are undergoing dyalisis. ^[@ref13]^ In this context, few studies have evaluated the presence and factors associated with the severity of pruritus in these patients. For this reason, it is necessary to perform an investigation that can determine the factors associated with the presence and severity of pruritus in the peruvian population undergoing hemodialysis.

Materials and Methods {#sec1-2}
=====================

Type of Research and design {#sec2-1}
---------------------------

Analytical cross-sectional study in patients receiving hemodialysis from the Centro Nacional de Salud Renal (CNSR).

Population {#sec2-2}
----------

The study population included 282 patients with terminal chronic kidney disease on hemodialysis treated at the Centro Nacional de Salud Renal (CNSR), registered in July 2017, of whom 264 agreed to participate in the study. Minors and individuals with a history of a previous dermatological condition were excluded, as were those who did not give informed consent.

Data Collection {#sec2-3}
---------------

A survey was developed that included the age and sex of the patient, the time on hemodialysis, and the Visual Analogue Scale (VAS) for pruritus which determines that an itch is severe when the score obtained is greater than or equal to 7.^[@ref14]^ This survey was applied during the months of July and August of 2017. The rest of the variables were obtained directly from the database of the Centro Nacional de Salud Renal (CNSR) through a data collection sheet.

Processing and Data Analysis {#sec2-4}
----------------------------

The population was described using measures of central tendency (mean and median), distribution (Standard Deviation, SD), and Interquartile Range (IQR) for numeric variables. For the categorical variables, the frequencies and percentages were reported. Next, a bivariate analysis was conducted using chi-squared and Fisher's exact tests for the corresponding categorical variables, and the significance level was set at p\<0.05. The crude and adjusted Prevalence Ratio (PR) values were calculated with their respective confidence intervals using Poisson regression analysis with robust error variance.

Ethical aspects {#sec2-5}
---------------

The study was approved by the Ethics Committee of the Hospital Nacional Edgardo Rebagliati Martins and by the Research Committee of the Centro Nacional de Salud Renal (CNSR). In addition, subjects had to sign a consent form in order to ensure the anonymity of the study and to secure the management of personal information.

Results {#sec1-3}
=======

264 individuals were recruited to participate in the study. Regarding their clinical profile, most patients were male (59.9%), with an average age of 52.17 ± 15.32 years. Likewise, the mean time of hemodialysis was 10.26 ± 7.14 years. Furthermore, 73.9% (195/264) of the individuals reported pruritus at the time of the study ([Table 1](#table001){ref-type="table"}).

In relation to the characteristics of the patients who suffered pruritus, the average score on the visual analog scale was 5.56 ± 2.3, and, according to the cut-off point proposed in the study, 1 in 3 experienced severe itching. Additionally, it was determined that 81 patients who had pruritus symptom presented positive serology for Hepatitis C Virus. Regarding calcium and phosphorus values, 27.1% and 37.2% presented hypercalcemia and hyperphosphatemia respectively. On the other hand, almost 1 in 4 patients suffered from anemia, and with respect to the use of medications, 4.1% of patients used Gabapentin and 49.2% antihistamines to control their pruritus ([Table 2](#table002){ref-type="table"}). [Table 3](#table003){ref-type="table"} shows the results of the bivariate analysis. It established that high serum phosphorus levels, the dose of dialysis, the use of gabapentin and the use of antihistamines were associated with severe pruritus (p \<0.05), defined as a score greater than or equal to 7 on the analog visual scale.

The results of the multivariate analysis are shown in [Table 4](#table004){ref-type="table"}, after adjusting for sex, age, time on hemodialysis, laboratory values and medication, it was established that hyperphosphatemia (PR 1.78, 95% CI 1.13-2.79) and the use of antihistamines (PR 2.48, 95% CI 1.56-3.94), were associated with a greater severity of pruritus. Contrariwise, a positive serology for Hepatitis C Virus (PR 0.55, 95% CI 0.33-0.89) was determined to be a protective factor for severe itching.

###### 

Characteristics of patients with end-stage renal disease (n = 264).

                                 n (%)
  ------------------ ----------- ---------------
  Age                Mean (SD)   52.17 (15.32)
  Gender             Male        158 (59.9)
                     Female      106 (40.1)
  Time in dialysis   Mean (SD)   10.26 (7.14)
  Pruritus           Yes         195 (73.9)
                     No          69 (26.1)

###### 

Dialysis dose, pruritus intensity and electrolyte values of patients with itching (n = 195).

                                                 n (%)
  ----------------------- ---------------------- -------------
  Hypercalcemia           Yes                    51 (27.1)
                          No                     137 (72.9)
  Hyperphosphatemia       Yes                    68 (35.8)
                          No                     122 (64.2)
  Hypoalbuminemia         Yes                    70 (37.2)
                          No                     118 (62.8)
  Excess of Ferritin      Yes                    184 (95.3)
                          No                     9 (4.7)
  Score (VAS)             Mean (SD)              5.56 (2.29)
  Itching (Intensity)     Severe                 68 (34.9)
  (n=195)                 Non severe             127 (65.1)
  Anemia                  Yes                    46 (23.6)
  Dialysis dose           No                     149 (76.4)
                          kt/V low (\< 1,3)      33 (18.1)
                          conventional (≥ 1,3)   149 (81.9)
  Use of gabapentin       Yes                    8 (4.1)
                          No                     187 (95.9)
  Use of antihistamines   Yes                    96 (49.2)
                          No                     99 (50.8)
  Hepatitis C             Yes                    81 (41.5)
                          No                     114 (58.5)
  CRP (mg/dL)             Mean (SD)              0.97 (2.05)

Some numbers may not add up due to missing values.

###### 

Association between the characteristics and the severity of pruritus.

  Characteristics of patients with terminal chronic kidney disease                               Pruritus patients (n=195)                           
  ------------------------------------------------------------------ --------------------------- --------------------------- ------- ------- ------- --------------------------------------------
  Age                                                                Mean (SD)                   53.07                       15.23   52.18   15.12   0.69^[\*](#tfn1){ref-type="table-fn"}^
  Gender                                                             Male                        45                          66.2    76      59.8    0.39^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     Female                      23                          33.8    51      40.2    
  Hepatitis C serology                                               Yes                         19                          27.9    62      48.8    0.005^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          49                          72.1    65      51.2    
  Dialysis time                                                      Mean (SD)                   10.54                       6.59    11.04   7.62    0.65^[\*](#tfn1){ref-type="table-fn"}^
  Dialysis dose                                                      kt/V low (\< 1,3)           17                          27.0    16      13.4    0.02^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     kt/V conventional (≥ 1,3)   46                          73.0    103     86.6    
  Laboratory characteristics                                                                                                                         
  Anemia                                                             Yes                         15                          22.1    31      24.4    0.71^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          53                          77.9    96      75.6    
  Hypercalcemia                                                      Yes                         20                          29.8    31      25.6    0.53^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          47                          70.2    90      74.4    
  Hyperphosphatemia                                                  Yes                         33                          48.5    35      28.7    0.006^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          35                          51.5    87      71.3    
  Hypoalbuminemia                                                    Yes                         25                          36.8    45      37.5    0.92^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          43                          63.2    75      62.5    
  Excess of Ferritin                                                 Yes                         64                          94.1    120     96.0    0.55^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          4                           5.9     5       4.0     
  CRP (mg/dL)                                                        Mean (SD)                   1.08                        1.71    0.85    1.64    0.35^[\*](#tfn1){ref-type="table-fn"}^
  Use of medication                                                                                                                                  
  Gabapentine                                                        Yes                         6                           8.8     2       1.6     0.02^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          62                          91.2    125     98.4    
  Antihistamines                                                     Yes                         46                          67.6    50      39.4    0.0001^[\*\*](#tfn2){ref-type="table-fn"}^
                                                                     No                          22                          32.4    77      60.6    

^\*^T-test.

^\*\*^ Chi squared.

Discussion {#sec1-4}
==========

Because pruritus constitutes a frequent comorbidity in patients with terminal chronic kidney disease and how it impacts their quality of life, it is important to determine its prevalence in our population. While several studies indicate that the prevalence of pruritus ranges from 20 to 90%;^[@ref8],[@ref9]^ in Peru, a previous study by Herrera-Añazco *et al*. estimated a prevalence of uremic pruritus in hemodialysis patients of 37.2%,^[@ref12]^ a number much lower than the one found in our investigation (73.9%), besides, this also represents the first peruvian study that has managed to assess its severity. In that sense, the DOPPS study, the most extensive and important research in relation to uremic pruritus, not only due to the large number of patients included around the world, but also, in addition to reporting the prevalence of pruritus, had also categorized itching according to intensity, albeit using a Likert scale; according to their findings, the prevalence of "moderate to extreme" pruritus was 42%,^[@ref8],[@ref9]^ a result very similar to ours.

Regarding the factors that are associated with the severity of pruritus, our multivariate analysis showed that hyperphosphatemia and the use of antihistamines were associated with the presence of severe itching. The relationship between the use of antihistamines and the presence of severe pruritus is expected, given that a more intense itching requires management beyond topical therapy, for example, the use of oral medications, including antihistamines, which according to some studies, have shown to reduce uremic pruritus and improve the quality of life.^[@ref15]^ Nevertheless, that antihistaines are generally considered as ineffective in uremic itch and this could be a major reason, why patients having these medications suffered from more severe itch. Our study also found that hyperphosphatemia increases the prevalence of severe pruritus, which correlates to other investigations, as well as being part of the pathophysiology of chronic renal failure. ^[@ref8],[@ref9]^ Concerning comorbid hepatic infection, it has been described that patients on hemodialysis and peritoneal dialysis show a higher frequency of Hepatitis C infection rather than Hepatitis B, nonetheless, both viruses are associated with a greater presence of moderate to severe pruritus compared to uninfected patients.^[@ref9],[@ref16]^ It is known that pruritus in individuals infected with HCV is produced by virus-induced cholestasis, as well as an increase in chemokines (CCL2, CXCL1 and CXCL5) and cytokines (primarily IL8), both as a result of high viral counts, which constitutes an active HCV infection.^[@ref17]^ In contrast to what is described above, our study determines that a positive serology for HCV is a protective factor for the development of severe pruritus. This suggests that it is not enough to describe a positive serological result, but rather to determine disease activity by measuring viral load.

###### 

Crude and adjusted analysis between the characteristics and severity of pruritus in patients with end-stage renal disease.

  Variables                                                 Patients considered for multivariate analysis (n=195) ^[\*](#tfn3){ref-type="table-fn"}^                               
  ------------------------------------- ------------------- ------------------------------------------------------------------------------------------ -------- ------------------ --------
  Characteristics of the participants                                                                                                                                              
  Age                                   (years)             1.00 (0.99-1.02)                                                                           0.69     1.01 (0.99-1.03)   0.10
  Gender                                Female              Ref                                                                                        Ref      Ref                Ref
                                        Male                1.19 (0.79-1.81)                                                                           0.39     1.36 (0.87-2.14)   0.18
  Hepatitis C serology                  No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 0.55 (0.33 -- 0.89)                                                                        0.008    0.55 (0.33-0.89)   0.016
  Dialysis time                         (years)             0.99 (0.97-1.02)                                                                           0.63     1.00 (0.97-1.04)   0.88
  Dialysis dose                         kt/V conventional   Ref                                                                                        Ref      Ref                Ref
                                        kt/V low            1.67 (1.11-2.51)                                                                           0.01     1.18 (0.69-2.01)   0.55
  Laboratory characteristics                                                                                                                                                       
  Anemia                                No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 0.92 (0.57-1.47)                                                                           0.72     0.99 (0.59-1.66)   0.99
  Hypercalcemia                         No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 1.14 (0.76-1.73)                                                                           0.53     1.02 (0.70-1.51)   0.88
  Hyperphosphatemia                     No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 1.69 (1.17-2.46)                                                                           0.006    1.71 (1.09-2.67)   0.018
  Hypoalbuminemia                       No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 0.98 (0.66-1.46)                                                                           0.92     1.09 (0.69-1.69)   0.71
  Excess of Ferritin                    No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 0.78 (0.37-1.67)                                                                           0.53     0.81 (0.41-1.61)   0.71
  CRP                                   (mg/dL)             1.05 (0.96-1.14)                                                                           0.32     0.95 (0.78-1.15)   0.58
  Use of medications                                                                                                                                                               
  Gabapentin                            No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 2.26 (1.44-3.55)                                                                           0.0001   1.36 (0.79-2.32)   0.26
  Antihistamines                        No                  Ref                                                                                        Ref      Ref                Ref
                                        Yes                 2.16 (1.41-3.29)                                                                           0.0001   2.39 (1.51-3.79)   0.0001

^[\*](#tfn3){ref-type="table-fn"}^ Poisson regression analysis with robust error variance.

^[\*\*](#tfn4){ref-type="table-fn"}^ (n = 195) crude.

^[\*\*\*](#tfn5){ref-type="table-fn"}^ (n = 178) adjusted.

We did not find an association between severe pruritus and risk factors such as hypercalcemia, hypoalbuminemia, anemia, the presence of pro-inflammatory markers such as CRP, among others.^[@ref10],[@ref11],[@ref21]^ More recent studies have included other variables, for example, a high white blood cell count or the presence of xerosis.^[@ref22]^ In 2019 Ersoy and Akyar found a higher pruritus severity score both in patients over 65 years and those in hemodialysis for 15 years or more.^[@ref23]^ These results differ from the findings of our study where no association was found between the severity of itching and the patient's mean time in hemodialysis.

In conclusion, pruritus is a common phenomenon in patients with terminal chronic kidney disease; its severity is associated with a significant and progressive deterioration in the quality of life of patients undergoing hemodialysis. This study demonstrates the magnitude of the problem in the patients of the Centro Nacional de Salud Renal (CNSR) and encourage the need for interdisciplinary management between nephrologists and dermatologists to prevent and treat it.

Scope and limitations {#sec2-6}
---------------------

In addition to reporting the prevalence and severity of uremic pruritus in patients with terminal chronic kidney disease, it is also important to define its impact on the quality of life of the patients. Many studies have attempted to answer this question, using a series of surveys that are difficult to apply in daily practice. However, recently a new 27-item questionnaire has been designed, the UP-Dial, which assesses uremic pruritus in all its dimensions (23). As a continuation of this investigation, this new tool could be validated in the previously studied population. Likewise, it would be interesting to make a comparison between hemodialysis and peritoneal dialysis.

This study has some limitations. First, because it is a cross-sectional study, a causal relationship between the variables studied cannot be established. Likewise, it was not possible to analyze some factors associated with severe uremic pruritus, which could have enriched the analysis.
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